Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages 931-942

  Sant, Milena ^a   Minicozzi, Pamela ^a   Mounier, Morgane ^b   Anderson, Lesley A ^c   Brenner, Hermann ^d   Holleczek, Bernd ^e   Marcos Gragera, Rafael ^f   Maynadié, Marc ^b   Monnereau, Alain ^g,h   Osca Gelis, Gemma ^f   Visser, Otto ⁱ   De Angelis, Roberta ^j  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e SAARLAND CANCER REGISTRY   (Germany)

^f GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^g INSTITUT BERGONIÉ   (France)

^h INSERM   (France)

ⁱ Centre d'Investigation Clinique ^*  (Netherlands)

^j ISTITUTO SUPERIORE DI SANITÀ   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; EASTERN EUROPE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOPROLIFERATIVE NEOPLASM; OBSERVATIONAL STUDY; PLASMACYTOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; SOUTHERN EUROPE; UNITED KINGDOM; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; EUROPE; FEMALE; HEMATOLOGIC NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; REGISTER; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CAUSE OF DEATH; COHORT STUDIES; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84905005458     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70282-7     Document Type: Article

References (34)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
2. Plosker GL, Figgitt DP Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63:803-843.
3. Thomas DA, O'Brien S, Kantarjian HM Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009, 23:949-971.
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
5. Armand JP, Burnett AK, Drach J, Harousseau JL, Löwenberg B, San Miguel J The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. Oncologist 2007, 12:281-290.
6. Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007, 4. CD003805.
7. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
8. Monnereau A, Troussard X, Belot A, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer 2013, 132:2378-2387.
9. EUROCARE Survival of cancer patients in Europe, (accessed May 5, 2014). http://www.eurocare.it.
10. Manual for coding and reporting Haematological Malignancies. Tumori 2010, 96:i-A32. HAEMACARE Working Group.
11. Fritz A, Percy C, Jack A, et al. International classification of disease for oncology (ICD-O) 2000, World Health Organization, Geneva. 3rd edn.
12. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn (WHO Classification of Tumours, Volume 2) 2008, World Health Organization, Geneva.
13. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014, 15:23-34.
14. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic sub-type: results of the HAEMACARE Project. Blood 2010, 116:3724-3734.
15. Dickman PW, Sloggett A, Hills M, Hakulinen T Regression models for relative survival. Stat Med 2004, 23:51-64.
16. Brenner H, Rachet B Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer 2004, 40:2494-2501.
17. Ederer F, Heise H. Instructions to IBM 650 Programmers in processing survival computations. Methodological note No. 10. End Results Evaluation Section. National Cancer Institute, Bethesda, MD; 1959.
18. Baili P, Micheli A, Montanari A, Capocaccia R Comparison of four methods for estimating complete life tables from bridge life tables using mortality data supplied to EUROCARE-3. Math Popul Stud 2005, 12:183-198.
19. Corazziari I, Quinn MJ, Capocaccia R Standard cancer patient population for age standardizing survival ratios. Eur J Cancer 2004, 40:2307-2316.
20. Krause SW, Gerken M, Andreesen R, Hofstädter F, Klinkhammer-Schalke M Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. Ann Hematol 2012, 91:561-570.
21. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
22. Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010, 28:4170-4176.
23. Wilking N, Jönsson B, Högberg D Comparator report on patient access to cancer drugs in Europe (accessed May 19, 2014). http://www.lmi.no/dm_documents/comparator_report_on_patient_access_to_cancer_drugs_in_europe_jan_15_09_wbkfi.pdf.
24. Pulte D, Gondos A, Redaniel MT, Brenner H Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population based cancer registries. Oncologist 2011, 16:663-671.
25. De Vita, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587-595.
26. Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013, 31:592-598.
27. Azoulay E, Mokart D, Pène F, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-a groupe de recherche respiratoire en réanimation onco-hématologique study. Clin Oncol 2013, 31:2810-2818.
28. Brenner H, Gondos A, Pulte D Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 2008, 111:4916-4921.
29. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
30. Pulte D, Gondos A, Brenner H Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011, 16:1600-1603.
31. Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study. Lancet Oncol 2014, 15:35-47.
32. Maynadié M, De Angelis R, Marcos-Gragera R, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica 2013, 98:230-238.
33. Cohen MH, Moses ML, Pazdur R Gleevecä for the treatment of chronic myelogenous leukemia: U.S. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Oncologist 2002, 7:390-392.
34. Brenner H, Hakulinen T Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002, 20:826-832.